Skip to content
Medical Health Aged Care, National News Current Affairs

New pack sizes for Panadol

Haleon ANZ 3 mins read
  • New Panadol pack sizes appearing on shelf in retail stores and pharmacies across Australia
  • Complying with the Therapeutic Goods Administration (TGA) scheduling decision for paracetamol that seeks to minimise the risk of harm from intentional misuse
  • Haleon is acting responsibly by implementing this roll out well ahead of the legislative effective date
  • New pack sizes will start to appear on shelf from late October 2024
  • Consumers can be reassured that there is no change to the suitability profile and efficacy of paracetamol for pain relief when used as directed

 

Friday 25 October 2024, Sydney, Australia: Haleon, the makers of Panadol (containing paracetamol as the active ingredient), is rolling out new Panadol pack sizes ahead of upcoming legislative changes that aim to minimise the risk of harm from intentional misuse of paracetamol in Australia.

 

The changes are in response to the decision by the TGA in 2023 to reduce the maximum available pack sizes of paracetamol-containing medicines for general sale and self-selection in pharmacies.

 

From 1 February 2025, the changes are as follows:

 

 

These changes apply to single active and paracetamol-containing combination tablets and capsules, such as cold and flu preparations.

 

The legislative effective date for changes to scheduling controls for access and sale is 1 February 2025, but some of the new Panadol packs have already started to appear on shelves.

 

Paracetamol remains a suitable and effective pain relief option. It is the most widely used pain relief medicine available without a prescription. Paracetamol has wide-ranging suitability for the majority of Australians.1

 

Elena Pintado, Head of Pain from Haleon ANZ, says the company has been working hard behind the scenes to implement these changes and ensure no disruption to supply.

 

"Our focus is always on the health of Australians and facilitating responsible self-care. As the makers of Panadol, Australia's number one trusted pain relief brand2, we take our responsibility very seriously to ensure Australians can continue to access Panadol without disruption as these changes come into effect,” said Ms Pintado.

 

“It is important to provide reassurance to Australians that there is no change to the suitability profile and efficacy of paracetamol for pain relief when used as directed,” added Ms Pintado.

 

Painaustralia Ambassador and former National Health Reporter for the ABC, Sophie Scott, in paid partnership with Haleon Australia, encourages people to always follow the instructions on the pack when taking over-the-counter medicines to relieve pain.

 

“Everyday pain affects a large number of Australians and paracetamol is widely used to manage it. Paracetamol is effective for everyday pain relief when used as directed. It is important that we follow the instructions on the pack and consult a healthcare professional if our pain persists,” added Ms Scott.

 

Over the counter analgesics should not be used for more than a few days at a time. If pain persists it is important to consult a healthcare professional.

 

Always read the label and follow the directions for use. Incorrect use could be harmful.

 

ENDS

MEDIA CONTACTS

Sarah Rumsey

Palin Communications

0488 060 047

sarah@palin.com.au

Ellen Hahn

Palin Communications

0414 674 743

ellen@palin.com.au

 

ABOUT HALEON

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands are built on trusted science, innovation and deep human understanding. For more information, please visit www.haleon.com.

 

REFERENCES

  1. Clarke, G. D. et al, (2008). Using suitability profiles to better inform consumers’ choice of commonly used over-the counter analgesics. Int J Pharm Pract, 16(5), 333-336 (GSK sponsored study). Accessed June 2024.
  2. Reader’s Digest Trusted Brands Survey 2024

 

Panadol contains paracetamol. Use: For the temporary relief of pain. Reduces fever. 

* Queensland and Western Australia Poisons regulations governing the storage and display of medicines available only in Pharmacies (i.e., S2 medicines) differ from the other states and territories.

Suitability based on criteria derived from contraindications, warnings and precautions from the product labelling and prescribing information for OTC paracetamol, and on Australian population demographics of 2006.

More from this category

  • Biotechnology, National News Current Affairs
  • 13/11/2024
  • 17:09
Jane Morgan Management

ASX listed BlinkLab to Participate in the Landmark Monash University Autism/ADHD MAGNET Project

BlinkLab Limited (ASX:BB1) (“BlinkLab”, “the Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological conditions, is pleased to announce their participation in the landmark MAGNET (Monash Autism & ADHD Genetics and Neurodevelopment) study conducted by Monash University’s School of Psychological Sciences. Link: https://molecularautism.biomedcentral.com/articles/10.1186/s13229-021-00457-3.Highlights The MAGNET project is an ongoing large cohort study aiming to enrol 1,000 families with children diagnosed with only autism, only ADHD, or with both autism and ADHD. MAGNET is utilising a novel family-based trial design where the parents, affected child and siblings (either affected or unaffected) are all enrolled in the…

  • Medical Health Aged Care, Research Development
  • 13/11/2024
  • 16:30
Australian Cardiovascular Alliance

Federal Government Boosts Australian Cardiovascular Alliance’s Mission to Combat Cardiovascular Disease and Stroke

The Australian Cardiovascular Alliance (ACvA) has received vital Federal funding to advance its innovative national approach addressing cardiovascular disease (CVD) and stroke. The Australian Government funding will bolster ACvA’s work to align research with health system priorities and facilitate multi-stakeholder collaborations. Cardiovascular Disease (CVD) and stroke remain the leading causes of death in Australia and worldwide, with CVD impacting the lives of one in six Australians and accounting for around $14 billion in direct health care costs. Addressing the burden of CVD facing the Australian community requires a step change in how we approach challenges of this scale. A key…

  • National News Current Affairs, Religion
  • 13/11/2024
  • 15:55
Ahmadiyya Muslim Community

VOICES FOR PEACE UNITE AT COMMUNITY SYMPOSIUM IN BLACKWOOD

The Elder’s Auxiliary of theAhmadiyya Muslim Community (Adelaide South Chapter) will hold its annual peace symposium, Voices for Peace Symposium, at 1:30 PM on…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.